Recruiting
Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia
ClinicalTrials.gov IDNCT06643130
PhasePHASE3
Enrollment162
SponsorJW Pharmaceutical
Age19 Years and older
SexALL
Conditions studied
Hypertension, Dyslipidemia
About this study
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia
Interventions
- Drug: JW0104+C2402 — For 8 weeks(PO (Per Oral), QD)
- Drug: JW0104+C2403 — For 8 weeks(PO, QD)
- Drug: C2402 — For 8 weeks(PO, QD)
Primary outcomes
- Change from baseline in msSBP (Systolic Blood Pressure) (week 8)
- Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol) (week 8)
Eligibility information
Inclusion Criteria:
* Patients with hypertension and dyslipidemia
Exclusion Criteria:
* The subject not meet the specified msBP and LDL-C level
Study locations
- Gangdong Sacred Heart Hospital, Seoul, 05355 South Korea
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.